Why the study?
Does triple antithrombotic therapy increase major bleeding compared to dual therapy or monotherapy in patients with atrial fibrillation?
Does triple antithrombotic therapy increase major bleeding compared to dual therapy or monotherapy in patients with atrial fibrillation?
Triple antithrombotic therapy in atrial fibrillation is associated with high major bleeding rates, warranting careful consideration especially in very elderly patients or those with high baseline risk.
High bleeding rates with triple therapy in atrial fibrillation warrant caution; leaves open optimal regimens pending randomized data.
Patients with atrial fibrillation on triple therapy experienced high rates of major bleeding in comparison with patients on dual therapy or monotherapy. The high bleeding rates observed in patients on triple therapy >90 years of age or with a CHA₂DS₂-VASc score >6 or with a history of a major bleeding warrants careful consideration of such therapy in these patients.
No takes yet. Share an insight, caveat, or question.
Rein et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Atrial fibrillationMore from Circulation